Skip to main content
KYNB
NASDAQ Life Sciences

Kyntra Bio Slashes Royalty Obligations by $60M, Extends Cash Runway to Q4 2027

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$7.65
Mkt Cap
$31.502M
52W Low
$6.32
52W High
$12.6
52W Position info
21% above low
Off High info
39% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

KYNB sits 21% above its 52-week low of $6.32.

Summary

Kyntra Bio restructured its royalty financing with NQ Project Phoebus, cutting maximum future payments from $125M to $65M via a $42.6M upfront payment. The deal reduces total liabilities by roughly $80M when combined with the FibroGen Europe bankruptcy settlement, and pro forma cash stands at $53.1M with runway into Q4 2027. This follows the Q2 10-Q that disclosed a Nasdaq delisting notice and a $30.9M bankruptcy gain, so the balance sheet cleanup is material for a company with a $31.5M market cap. The company also reiterated Phase 2 FG-3246 interim data expected in Q4 2026 and a pivotal roxadustat Phase 3 start in Q4 2026. The upfront payment consumes nearly half of reported cash, but the liability reduction and extended runway are net positives for solvency.

Updates

  1. · SEC 8-K — The 8-K states the amended agreement eliminates all future true-up payments and releases Japan royalties from collateral; remaining $15M obligation is payable from 50% of Astellas revenue excluding Japan.

At the time of this announcement, KYNB was trading at $7.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.5M. The 52-week trading range was $6.32 to $12.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

KYNB - Latest Insights

KYNB
Nov 16, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.00
Real-time Price: $2.91 info
Change: -$0.090 (-3%) info
Market Cap: $12.957M info
KYNB
Nov 16, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.20
Real-time Price: $2.91 info
Change: -$0.290 (-9%) info
Market Cap: $12.957M info
KYNB
Nov 16, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.20
Real-time Price: $2.91 info
Change: -$0.290 (-9%) info
Market Cap: $12.957M info
KYNB
Oct 06, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $5.96
Real-time Price: $2.91 info
Change: -$3.05 (-51%) info
Market Cap: $12.957M info
KYNB
Aug 31, 2026, 5:18 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.65
Real-time Price: $2.91 info
Change: -$4.74 (-62%) info
Market Cap: $12.957M info